Targeted nucleic acid conjugate compositions

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 11896672
APP PUB NO 20190160176A1
SERIAL NO

16092685

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention provides conjugates that comprise a targeting moiety, a nucleic acid, and optional linking groups as well as synthetic intermediates and synthetic methods useful for preparing the conjugates. The conjugates are useful to target therapeutic nucleic acids to the liver and to treat liver diseases including hepatitis (e.g. hepatitis B and hepatitis D).

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ARBUTUS BIOPHARMA CORPORATION100-8900 GLENLYON PARKWAY BURNABY BRITISH COLUMBIA V5J 5J8

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Heyes, James Vancouver, CA 67 4027
Holland, Richard J Vancouver, CA 41 499
Martin, Alan D Vancouver, CA 20 994
Wood, Mark Port Moody, CA 123 2599

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Aug 13, 2027
7.5 Year Payment $3600.00 $1800.00 $900.00 Aug 13, 2031
11.5 Year Payment $7400.00 $3700.00 $1850.00 Aug 13, 2035
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00